Company intelligence / Profile preview

Innnova-X

Ownership: Private
Development stage: Commercial

Overview

Innovax has commercialized the world’s first hepatitis E vaccine (Hecolin®), China’s first bivalent HPV vaccine (Cecolin®), and China’s first/world's second 9-valent HPV vaccine (Cecolin®9). Cecolin® received WHO prequalification in 2021 and is approved in over 20 countries, included in national immunization programs of at least seven countries. The company also has a cervical cancer candidate in phase III trials and a genital warts candidate in phase II trials.

Therapeutic areas: Infectious Diseases
Modalities: Prophylactic vaccineVirus-like particle vaccineMultivalent vaccineGenetically engineered subunit vaccineConjugated vaccine
Industry: Biotech

Partnerships

Xiamen University collaboration noted on clinical trial sponsorships.

Beyond the preview

Go deeper on Innnova-X.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Innnova-X.

Explore the full profile